Cardiol Therapeutics Inc Class A CRDL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $1.06
- Day Range
- $1.05–1.10
- 52-Week Range
- $0.88–1.71
- Bid/Ask
- $1.04 / $1.07
- Shares Outstanding
- 115.27M
- Market Cap
- $122.19M
- Volume/Avg
- 354,435 / 673,726
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 18
- Website
- https://www.cardiolrx.com
Valuation
|
Metric
|
CRDL
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 7.51 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CRDL
|
|---|---|
Quick Ratio | 3.93 |
Current Ratio | 4.39 |
Interest Coverage | — |
Quick Ratio
CRDL
Profitability
|
Metric
|
CRDL
|
|---|---|
Return on Assets (Normalized) | −105.33% |
Return on Equity (Normalized) | −152.66% |
Return on Invested Capital (Normalized) | −150.29% |
Return on Assets
CRDL
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| ARYx Therapeutics Inc
ARYX
| — | Dlhh | — | |||
| Merck KGaA
MKGAF
| — | Vbmpyg | $67B | |||
| Merck KGaA ADR
MKKGY
| Fkxpbpygby | Jppcdj | $67B | |||
| Galderma Group AG ADR
GALDY
| — | Wvqltb | $51B | |||
| Galderma Group AG Registered Shares
GDERF
| — | Xkngwk | $51B | |||
| Takeda Pharmaceutical Co Ltd
TKPHF
| — | Gxryv | $50B | |||
| Takeda Pharmaceutical Co Ltd ADR
TAK
| — | Vgg | $50B | |||
| Jiangsu Hengrui Pharmaceuticals Co Ltd ADR
JHPCY
| — | Djyjkxr | $47B | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| Frtmtvnmdn | Jldxgw | $40B | |||
| Teva Pharmaceutical Industries Ltd
TEVJF
| Bpvdvdx | Ktppccf | $40B |
United States